New frontiers in pharmacologic obstructive sleep apnea treatment: A narrative review.

@article{Schtz2021NewFI,
  title={New frontiers in pharmacologic obstructive sleep apnea treatment: A narrative review.},
  author={Sonja G. Sch{\"u}tz and Abbey E Dunn and Tiffany J Braley and Bertram Pitt and Anita Valanju Shelgikar},
  journal={Sleep medicine reviews},
  year={2021},
  volume={57},
  pages={
          101473
        }
}

Cardiovascular manifestations in obstructive sleep apnea: current evidence and potential mechanisms.

The role of personalized medicine, alternative treatment options, and precise phenotyping to optimize treatment of this complex condition and its associated cardiovascular risk are discussed.

Obstructive sleep apnea: transition from pathophysiology to an integrative disease model

A detailed understanding of the complex pathophysiology of OSA encourages the development of therapies targeted at pathophysiological endotypes and facilitates a move towards precision medicine as a potential alternative to continuous positive airway pressure therapy in selected patients.

Elements of Diagnosis and Non-surgical Treatment of Obstructive Sleep Apnea in Adults from the Dental Medicine Perspective

Current topics in modern scientific research include the evaluation of standard, even higher doses of single agents or the combination of different agents on the evolution of OSA, as well as the assessment of the association of diverse pharmacotherapy agents with other OSA therapies.

Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications

The impact of dapagliflozin on cardiovascular risk factors and common microangiopathic complications such as kidney disease and retinopathy in patients with T2DM is addressed and its potential beneficial effects on other less frequent complications of diabetes are evaluated.

Comprehensive analysis of differentially expressed miRNAs in mice with kidney injury induced by chronic intermittent hypoxia

The findings advance the understanding of the molecular regulatory mechanisms underlying the pathophysiology of obstructive sleep apnea-associated chronic kidney disease.

Schlafbezogene Atmungsstörungen – Update 2021

Schlafbezogene Atmungsstörungen (SBAS) und andere Schlafstörungen sind sehr häufige Erkrankungen, die zu erheblichen Einbußen hinsichtlich der Lebensqualität, Arbeitsfähigkeit und Prognose beitragen

References

SHOWING 1-10 OF 90 REFERENCES

Diagnosis and Management of Obstructive Sleep Apnea: A Review.

Effective treatments for obstructive sleep apnea include weight loss and exercise, positive airway pressure, oral appliances that hold the jaw forward during sleep, and surgical modification of the pharyngeal soft tissues or facial skeleton to enlarge the upper airway.

The pharmacotherapeutic management of obstructive sleep apnea

The authors are concerned about the risk that, treating only EDS, patients could reduce their compliance to CPAP, thus not reducing the cardiovascular risk associated with OSA, and underlines the importance to avoid considering the pathology like a single entity without any differences between each single form.

Practice parameters for the medical therapy of obstructive sleep apnea.

No practice parameters could be developed for a number of possible therapeutic modalities that had little or no evidence-based data on which to form a conclusion, and the role of an organized, targeted weight-loss program either as a single therapy or as a supplement to PAP needs to be clarified.

CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea.

Therapy with CPAP plus usual care, as compared with usual care alone, did not prevent cardiovascular events in patients with moderate-to-severe obstructive sleep apnea and established cardiovascular disease.

Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study.

The strong adjusted association between ischemic stroke and OAHI in community-dwelling men with mild to moderate sleep apnea suggests that this is an appropriate target for future stroke prevention trials.

Relationship Between Overnight Rostral Fluid Shift and Obstructive Sleep Apnea in Drug-Resistant Hypertension

The concept that fluid redistribution centrally during sleep accounts for the high prevalence of obstructive sleep apnea in drug-resistant hypertension in hypertensive subjects is supported.

Efficacy of mirtazapine in obstructive sleep apnea syndrome.

The findings suggest the therapeutic potential of mixed-profile serotonergic drugs in OSA and provide support for future studies with related formulations, but do not recommend use of mirtazapine as a treatment for OSA.

Treating obstructive sleep apnea with hypoglossal nerve stimulation.

HGNS demonstrated favorable safety, efficacy, and compliance in treating obstructive sleep apnea and participants experienced a significant decrease in OSA severity and OSA-associated symptoms.

Acetazolamide Reduces Blood Pressure and Sleep-Disordered Breathing in Patients With Hypertension and Obstructive Sleep Apnea: A Randomized Controlled Trial.

AZT reduced blood pressure, vascular stiffness, andSleep Apnea Associated Hypertension and Vascular Dysfunction in patients with OSA and comorbid hypertension.
...